Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ENDRA LIFE SCIENCES INC (NDRA)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$5.00+1.32%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for NDRA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Successfully complete merger agreement with ASP Isotopes Inc. | A primary condition in ENDRA LIFE SCIENCES INC's published investment case. The stated target is Merger completed by end of 2026. | Intact | Merger agreement is terminated or fails to close by end of 2026 | Merger active (S-4 filed Oct 2026) vs target: complete by end-2026 ASP Isotopes filed S-4 for the planned merger in Oct 2026, following an amendment to the merger agreement. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making business with volatile management and high risk, rather than an established compounder. The current thesis state is watch, with low confidence and financial performance well below its industry cohort.
The evidence does not provide a valuation measure or show what expectations are reflected in the valuation, so the market’s assumptions cannot be assessed reliably. The muted reaction to recent developments does not establish whether the shares are cheap, fair, or expensive versus peers.
Near term, weak recent performance and repeated earnings misses leave elevated risk of another miss. Expense cuts reduced research and development and sales and marketing costs, while operating cash use also declined year over year, but management’s expense and cash-management priority is still rated behind. The merger with Noble Africa remains on track for an expected Q4 2026 close, subject to stockholder and regulatory approvals.
The multi-year thesis hinges on completing the merger and related financing, and on whether expense and cash management can improve without undermining the business. Near-term sector signals are mixed: stronger results and guidance from healthcare bellwethers could sustain a sector tailwind, while weaker jobs data or missed guidance could add pressure.
Over the next 1 to 3 years, NDRA’s long-term thesis remains uncertain and depends on merger execution and evidence of stronger financial performance. The available evidence is limited, and near-term earnings risk is elevated. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Meet Nasdaq minimum stockholders' equity requirements |
| A supporting condition in ENDRA LIFE SCIENCES INC's published investment case. The stated target is Stockholders' equity >= $2.5M. |
| Intact |
| Stockholders' equity remains below $2.5M by end of 2026 |
Total equity: $6.31M FY2026-Q2; GAAP. Published target: Stockholders' equity >= $2.5M. Target period is not explicitly aligned with this observation. Aug 14, 20266,309,691 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Narrow net loss to less than -$1.31M | A primary condition in ENDRA LIFE SCIENCES INC's published investment case. The stated target is >= -1,310,000 USD net loss. | Recovered | net loss exceeds -$1.31M in any quarter after 2026-Q2 | Net income: $159,944 FY2026-Q2; GAAP. Published target: >= -1,310,000 USD net loss. The target does not explicitly identify fiscal versus calendar quarters. Aug 14, 2026159,944 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce cash burn to less than -$1.12M in operating cash flow | It has cut costs, reducing cash burn from -$1.62M to -$1.12M in operating cash. | Broken | operating cash flow falls below -$1.12M in any quarter after 2026-Q2 | Cash from operations: $-927,560 FY2026-Q2; GAAP. Published target: >= -1,120,000 USD operating cash flow. The target does not explicitly identify fiscal versus calendar quarters. Aug 14, 2026-927,560 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.04 → $-3.04 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.04 | $200,000 | 1 / 1 |
| 2026-07-25 | $-3.04 | $200,000 | 1 / 1 |
| 2026-07-26 | $-3.04 | $200,000 | 1 / 1 |
| 2026-07-27 | $-3.04 | $200,000 | 1 / 1 |
| 2026-07-28 | $-3.04 | $200,000 | 1 / 1 |
| 2026-07-29 | $-3.04 | $200,000 | 1 / 1 |
| 2026-07-30 | $-3.04 | $200,000 | 1 / 1 |
| 2026-07-31 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-01 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-02 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-03 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-04 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-05 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-06 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-07 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-08 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-09 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-10 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-12 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-13 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-14 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-15 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-16 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-17 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-18 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-19 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-20 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-21 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-22 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-23 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-24 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-25 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-26 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-27 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-28 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-29 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-30 | $-3.04 | $200,000 | 1 / 1 |
| 2026-08-31 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-01 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-02 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-03 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-04 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-05 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-06 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-07 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-08 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-09 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-10 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-11 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-12 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-13 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-14 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-15 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-16 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-17 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-18 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-19 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-20 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-21 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-22 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-23 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-24 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-25 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-26 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-27 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-28 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-29 | $-3.04 | $200,000 | 1 / 1 |
| 2026-09-30 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-01 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-02 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-03 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-04 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-05 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-06 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-07 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-08 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-09 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-10 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-11 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-12 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-13 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-14 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-15 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-16 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-17 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-18 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-19 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-20 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-21 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-22 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-23 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-24 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-25 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-26 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-27 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-28 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-29 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-30 | $-3.04 | $200,000 | 1 / 1 |
| 2026-10-31 | $-3.04 | $200,000 | 1 / 1 |
| 2026-11-01 | $-3.04 | $200,000 | 1 / 1 |
| 2026-11-02 | $-3.04 | $200,000 | 1 / 1 |
| 2026-11-03 | $-3.04 | $200,000 | 1 / 1 |
| 2026-11-04 | $-3.04 | $200,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.